Heidelberg Pharma GmbH
Schriesheimer Street 101
Ladenburg
68526
Germany
Tel: 49-6203-10090
Website: http://www.heidelberg-pharma.com/
About Heidelberg Pharma GmbH
Heidelberg Pharma offers services for the pre-clinical development of anti-cancer and anti-inflammatory drugs to the pharmaceutical and biotech industry.YEAR FOUNDED:
1999
LEADERSHIP:
CEO and CFO: Jan Schmidt-Brand
CBO: Marcel Linssen
CSO: Andreas Pahl
JOBS:
Please click here for Heidelberg Pharma job opportunities.
36 articles about Heidelberg Pharma GmbH
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
2/28/2022
Heidelberg Pharma AG and Huadong Medicine Co., Ltd., Hangzhou, China, announced that the companies have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement.
-
Heidelberg Pharma AG Raises EUR 14.4 Million From Private Placement
4/27/2020
Heidelberg Pharma AG announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction.
-
Heidelberg Pharma Publishes Article on Chemical Amanitin Synthesis in Angewandte Chemie Journal
3/27/2020
Heidelberg Pharma AG announced that a scientific article on the chemical synthesis of the fungal compound Amanitin has been published in Angewandte Chemie, a leading chemical journal.
-
Heidelberg Pharma Announces Financial Figures for Fiscal Year 2019 and Provides Business Update
3/19/2020
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2019 and its outlook for 2020.
-
Heidelberg Pharma AG Secures Financing Commitment from Its Main Shareholder dievini
1/22/2020
Heidelberg Pharma AG announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany
-
Heidelberg Pharma Participates in Franco-German Joint Venture Emergence Therapeutics and Signs Collaboration and License Agreement
11/20/2019
Heidelberg Pharma contributing Antibody Targeted Amanitin Conjugate technology for Emergence Therapeutics antibody target
-
Partner Magenta Therapeutics Exercises Option to Further Develop Antibody Targeted Amanitin Conjugates Targeted to CD45
11/11/2019
Heidelberg Pharma AG announced that its partner Magenta Therapeutics, Cambridge, MA, USA, declared that it will exercise the option for the exclusive worldwide development and marketing rights for Antibody Targeted Amanitin Conjugates targeting CD45.
-
Heidelberg Pharma Announces Participation at Various Conferences
11/6/2019
Heidelberg Pharma AG announced that they will participate at the following investor events and scientific conferences.
-
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2019
10/10/2019
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group's financial figures.
-
Heidelberg Pharma AG Announces Adjustment of Guidance
10/2/2019
Heidelberg Pharma AG announced that it has adjusted its guidance for the current fiscal year published in March 2019.
-
Heidelberg Pharma receives European Union research grant for the ETN MAGICBULLET project
9/25/2019
Heidelberg Pharma AG announced that its subsidiary Heidelberg Pharma Research GmbH will receive a research grant from the European Union.
-
Heidelberg Pharma reports on first half-year
7/11/2019
Heidelberg Pharma AG published its financial report on the first six months of 2019
-
Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences
6/11/2019
Heidelberg Pharma AG announced that they will present their proprietary technology for Antibody Targeted Amanitin Conjugates as potential therapeutic modality for cancer therapy at two upcoming scientific conferences.
-
Heidelberg Pharma Receives Milestone Payment from Partner Telix
6/5/2019
Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.
-
Heidelberg Pharma Reports Outcome Of Annual General Meeting
5/21/2019
Heidelberg Pharma AG announced that the shareholders of the Company approved the resolutions of the administration with large majorities during the Annual General Meeting.
-
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2019
4/11/2019
Heidelberg Pharma AG reported on the first three months of fiscal year 2019 (1 December 2018 - 28 February 2019) and the Group's financial figures.
-
Heidelberg Pharma to present its proprietary ATAC technology platform at the AACR Annual Meeting 2019
3/27/2019
Heidelberg Pharma AG announced that it will present preclinical data on the application of its proprietary ATAC technology platform in the treatment of triple-negative breast cancer at the Annual Meeting of the American Association for Cancer Research 2019.
-
Heidelberg Pharma announces financial figures for fiscal year 2018 and provides business update
3/21/2019
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2018 and its outlook for 2019.
-
Heidelberg Pharma Receives Milestone Payment From Partner Link Health
1/22/2019
Heidelberg Pharma AG announced today that it has received a milestone payment from its cooperation partner Link Health Co., Guangzhou, China.